A U.S. patient suffering from advanced non-small cell lung cancer (NSCLC) and Parkinson’s disease has stabilized following treatment with a novel immunotherapy called ivonescimab at the Jiahui International Cancer Center (JICC) in Shanghai. The patient, in his seventies, had exhausted all standard treatment options at the renowned MD Anderson Cancer Center in the United States before seeking alternative therapies.
After a video consultation in late November 2025, the patient’s family opted for treatment at JICC, drawn by the center’s multidisciplinary team and the expertise of U.S.-trained Medical Oncology Chief, Dr. Xuan Linli. Ivonescimab, a PD-1/VEGF bispecific antibody designed for solid tumors, represents a cutting-edge approach in oncology, currently available exclusively in China.
During the treatment process, the patient faced immune-related complications that necessitated intensive care unit (ICU) support. The oncology team at JICC swiftly coordinated care across multiple specialties, including oncology, neurology, and critical care, with significant contributions from Dr. Zhou Caicun, the principal investigator for ivonescimab. As a result of their integrated efforts, the patient’s condition has stabilized, allowing for ongoing focus on disease control.
Innovative Cancer Care in Shanghai
Jiahui International Cancer Center is affiliated with Massachusetts General Hospital Cancer Center, which enhances its capacity to provide seamless international patient care. The center facilitates remote consultations, travel arrangements, and keeps families updated throughout the treatment journey. The patient’s daughter expressed profound gratitude for the comprehensive support her family received, stating, “We are deeply grateful for the dedication, compassion, and tireless efforts of the entire Jiahui team, especially to Ms. Cui, who has cared for my father every day since his admission.”
Innovative oncology treatments in China, such as ivonescimab, are increasingly attracting patients from around the globe, including referrals from North America, Europe, Asia, and the Middle East. This trend is establishing Shanghai as a prominent hub for advanced cancer care.
The successful stabilization of the patient demonstrates the potential of Chinese medical advancements to provide new options for individuals facing dire health challenges. As international inquiries into Jiahui’s capabilities grow, the center’s role in delivering cutting-edge cancer treatment is becoming more significant.
For further information about international patient services, interested parties can contact Jiahui International Cancer Center at [email protected] or via WhatsApp at +852 4619 1904.
